8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 5, 2026·SEC
Material company update
Jan 12, 2026·SEC
Bristol-Myers Squibb Company Ce(CELG-RI)Earnings, Financials & Key Ratios
CELG-RI•NYSE
$0.09
0.0× P/E·Price updated Jul 7, 2026
AboutBristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.Show more
- Revenue$48.19B-0.2%
- EBITDA$19.24B-0.1%
- Net Income$7.05B+178.8%
- EPS (Diluted)3.46+178.5%
- Gross Margin65.9%+16.0%
- EBITDA Margin39.92%+0.1%
- Operating Margin31.37%+56.9%
- Net Margin14.64%+179.0%
- ROE40.43%+203.6%
CELG-RI Price & Volume
Bristol-Myers Squibb Company Ce (CELG-RI) stock price & volume — 10-year historical chart
Loading chart...
Portfolio Transition Pressures Balance Sheet Stability Metrics
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Strained
Cash Flow:Mixed
Primary Risk:Patent Cliff Revenue Erosion
Key Thesis Takeaways
- Bristol-Myers Squibb faces a challenging transition period as it attempts to offset legacy asset erosion with a high-cost inorganic growth strategy.
- While the company maintains a 32.9% operating margin as of 2026Q1, the reliance on significant debt to fund acquisitions like Karuna and RayzeBio has constrained financial flexibility.
- Investors should monitor the company's ability to convert R&D investments into consistent revenue growth, as the current $21.7 billion goodwill balance poses a long-term risk to capital efficiency.
Verdict Logic
while the company maintains a 32.9% operating margin, the high debt-to-equity ratio of 2.21 and the volatility in free cash flow suggest that execution risks regarding the current acquisition-heavy strategy warrant a cautious approach.
CELG-RI Growth Metrics
Bristol-Myers Squibb Company Ce (CELG-RI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.27%
5 Years2.54%
3 Years1.45%
TTM1.78%
Profit CAGR
10 Years15.82%
5 Years-
3 Years3.69%
TTM34.25%
EPS CAGR
10 Years13.56%
5 Years-
3 Years5.46%
TTM33.57%
Return on Capital
10 Years14.31%
5 Years13.48%
3 Years15.68%
Last Year22.32%
CELG-RI Recent Earnings
Bristol-Myers Squibb Company Ce (CELG-RI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/9 qtrs (50%)●Beat Revenue 5/9 qtrs (100%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.58+11.3%
$1.42
Rev
$11.5B+5.1%
$10.9B
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$1.26+2.4%
$1.23
Rev
$12.5B+1.8%
$12.3B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$1.08-28.9%
$1.52
Rev
$12.2B+3.1%
$11.9B
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
—
$1.09
Rev
$12.3B+7.2%
$11.4B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.58vs $1.42+11.3% | $11.5Bvs $10.9B+5.1% |
| Q1 2026 | Feb 5, 2026 | $1.26vs $1.23+2.4% | $12.5Bvs $12.3B+1.8% |
| Q4 2025 | Oct 30, 2025 | $1.08vs $1.52-28.9% | $12.2Bvs $11.9B+3.1% |
| Q3 2025 | Jul 31, 2025 | —vs $1.09 | $12.3Bvs $11.4B+7.2% |
Based on last 9 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Bristol-Myers Squibb Company Ce (CELG-RI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.09 | $187.84M | 0.03 | -0.22% | 14.64% | 40.43% | 100% | |
| $57.97 | $118.36B | 16.80 | -0.22% | 15.01% | 38.96% | — | |
| $128.86 | $318.26B | 17.70 | 1.18% | 13.62% | 17.91% | — | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $193.12 | $299.39B | 29.53 | 8.63% | 17.19% | 22.24% | — | |
| $1235.56 | $1.17T | 53.84 | 44.7% | 34.98% | 101.17% | — |
Compare CELG-RI vs Peers
Bristol-Myers Squibb Company Ce (CELG-RI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CELG-RI SEC Filings & Documents
Bristol-Myers Squibb Company Ce (CELG-RI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CELG-RI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CELG-RI Frequently Asked Questions
Bristol-Myers Squibb Company Ce (CELG-RI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Bristol-Myers Squibb Company Ce's revenue?
Bristol-Myers Squibb Company Ce (CELG-RI) reported $48.48B in revenue for fiscal year 2025. This represents a 222% increase from $15.06B in 1996.
How fast is Bristol-Myers Squibb Company Ce growing?
Bristol-Myers Squibb Company Ce (CELG-RI) saw revenue decline by 0.2% over the past year.
Is CELG-RI profitable?
Yes, Bristol-Myers Squibb Company Ce (CELG-RI) is profitable, generating $7.28B in net income for fiscal year 2025 (14.6% net margin).
Dividend & Returns
Does CELG-RI pay dividends?
Yes, Bristol-Myers Squibb Company Ce (CELG-RI) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
What is CELG-RI's return on equity?
Bristol-Myers Squibb Company Ce (CELG-RI) has a return on equity (ROE) of 40.4%. This is excellent, indicating efficient use of shareholder capital.
What is Bristol-Myers Squibb Company Ce's free cash flow?
Bristol-Myers Squibb Company Ce (CELG-RI) generated $11.91B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.